Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
52
MRES Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
22.47%
Day range:
$0.0038 - $0.0070
52-week range:
$0.0016 - $0.0280
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
240.23x
P/B ratio:
21.74x
Volume:
142.1K
Avg. volume:
1.6M
1-year change:
-67.91%
Market cap:
$12M
Revenue:
$49.5K
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Institute of BioMedical Research Corp. has -- downside to fair value with a price target of -- per share.
MRES vs. S&P 500
-
Over the past 5 trading days, Institute of BioMedical Research Corp. has overperformed the S&P 500 by 75.81% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Institute of BioMedical Research Corp. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Institute of BioMedical Research Corp. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Institute of BioMedical Research Corp. reported revenues of --.
Earnings Growth
-
Institute of BioMedical Research Corp. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Institute of BioMedical Research Corp. reported earnings per share of --.
Enterprise value:
14M
EV / Invested capital:
--
Price / LTM sales:
240.23x
EV / EBIT:
--
EV / Revenue:
282.30x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-32.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $29.4K | $45.1K | $49.5K | $15.3K | $19.3K | |
| Gross Profit | $8.7K | $8.5K | $21.4K | $1.8K | $9.1K | |
| Operating Income | -$723.9K | -$1.8M | -$756.5K | -$1.2M | -$290.8K | |
| EBITDA | -$723.9K | -$1.8M | -- | -$1.2M | -$290.8K | |
| Diluted EPS | -$0.00 | $0.00 | -$0.00 | $0.00 | -$0.00 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $216.7K | $323.3K | $108.3K | |
| Total Assets | -- | -- | $637.9K | $3.5M | $3.3M | |
| Current Liabilities | -- | $117.5K | $283.1K | $935.3K | $682.7K | |
| Total Liabilities | -- | $637.4K | $759.1K | $935.3K | $775.7K | |
| Total Equity | -- | -$637.4K | -$121.2K | $2.6M | $2.5M | |
| Total Debt | -- | $266.9K | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$567.9K | -$313.8K | -$433.7K | -$40.2K | -$252.8K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $562.8K | $408.1K | $348.7K | $135.2K | $265.3K | |
| Free Cash Flow | -$567.9K | -$313.9K | -$433.7K | -$40.2K | -$252.8K | |
MRES
Sector
Market Cap
$12M
--
Price % of 52-Week High
17.86%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
-67.91%
--
Beta (5-Year)
-0.452
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.0035
200-day SMA
Sell
Level
$0.0104
Bollinger Bands (100)
Sell
Level
0.0064 - 0.0064
Chaikin Money Flow
Buy
Level
1.2M
20-day SMA
Buy
Level
$0.0040
Relative Strength Index (RSI14)
Buy
Level
53.5208
ADX Line
Buy
Level
18.3072
Williams %R
Neutral
Level
-39.3939
50-day SMA
Sell
Level
$0.0060
MACD (12, 26)
Buy
Level
0.0011
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-11.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.2821)
Sell
CA Score
(Annual)
Level (-2.3629)
Buy
Beneish M-Score
(Annual)
Level (-2.9983)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.8881)
Sell
Piotroski F Score
(Annual)
Level (3)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Institute of BioMedical Research Corp. engages in research and development, quality control and standardization of pharmaceuticals, cosmetics and food products. Its products include Aerosan, MicrobEX, Klenet microbicidal towels, OralNet and Oral Ocean Power mouthwash, Purilair, colloidal silver, electro medical devices, beauty devices, electrodes, and garment electrodes. It also offers quality control, regulatory, and health care services; environmental analyses; building decontamination; and environmental protection and management services. The company was founded on July 26, 1990 and is headquartered in Niksic, Montenegro.
Stock Forecast FAQ
In the current month, MRES has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRES average analyst price target in the past 3 months is --.
-
Where Will Institute of BioMedical Research Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Institute of BioMedical Research Corp. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Institute of BioMedical Research Corp.?
Analysts are divided on their view about Institute of BioMedical Research Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Institute of BioMedical Research Corp. is a Sell and believe this share price will rise from its current level to --.
-
What Is Institute of BioMedical Research Corp.'s Price Target?
The price target for Institute of BioMedical Research Corp. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MRES A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Institute of BioMedical Research Corp. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MRES?
You can purchase shares of Institute of BioMedical Research Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Institute of BioMedical Research Corp. shares.
-
What Is The Institute of BioMedical Research Corp. Share Price Today?
Institute of BioMedical Research Corp. was last trading at $0.0100 per share. This represents the most recent stock quote for Institute of BioMedical Research Corp.. Yesterday, Institute of BioMedical Research Corp. closed at $0.0050 per share.
-
How To Buy Institute of BioMedical Research Corp. Stock Online?
In order to purchase Institute of BioMedical Research Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MRES Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MRES
Sector
P/E ratio
--
--
PEG ratio
--
--
P/B ratio
21.74x
--
Price / LTM sales
240.23x
--
Growth Metrics
MRES
Sector
Revenue growth
--
--
Earnings growth
--
--
Revenue (5-year growth)
--
--
Earnings forecast
--
--
Profitability
MRES
Sector
Profitability FY 2024
$21.4K
--
Return on invested capital
--
--
Return on assets
--
--
Return on equity
--
--
Earnings Date
Last Earnings Date
Jan
12
Next Earnings Date
Jan
12
Estimated Next Earnings Date
Apr
13
Balance Sheet
MRES
Sector
Total cash
--
--
Short term investments
--
--
Total assets
$3.3M
--
Long term debt
--
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
